MNOV MEXC RealStocks
Own real MNOV shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-14 06:13:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Medicinova, Inc. (MNOV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.39, with a market capitalization of $68.91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.22 to $3.90. This page covers its latest market performance, valuation, price trends and company information.
$68.91M | |
$1.40 | |
$1.44 | |
$1.38 | |
$1.40 | |
60.99K | |
335.81K | |
-- | |
$3.90 | |
$1.22 | |
-- | |
-- |
Medicinova, Inc. (MNOV) last closed at $1.39 as of 2026-11-13 21:16:00, down 0.71% ($0.01) from the previous close of $1.40.
During the latest regular trading session, MNOV traded between $1.38 and $1.44, with a volume of 60.99K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Medicinova, Inc. (MNOV) moved from $1.45 to $1.39, representing a decline of 4.07% ($0.06).
The stock traded between $1.38 and $1.55 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 43.53 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 6.4%
MNOV is currently trading at $1.39, placing it 6.4% of the way from its 52-week low of $1.22 to its 52-week high of $3.90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Medicinova, Inc. (MNOV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MNOV, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MNOV shares and USD.
MNOV Shares to USD
1.00 MNOV shares = 1.391 USD
Calculations are estimates based on the latest available price and are for reference only.